losartan has been researched along with Aura in 10 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Excerpt | Relevance | Reference |
---|---|---|
" We propose losartan, a drug approved by the US Food and Drug Administration, as an efficient antiepileptogenic therapy for epilepsy associated with vascular injury." | 7.80 | Losartan prevents acquired epilepsy via TGF-β signaling suppression. ( Bar-Klein, G; Cacheaux, LP; Cheng, P; Friedman, A; Heinemann, U; Kamintsky, L; Kaufer, D; Kim, SY; Prager, O; Schoknecht, K; Weissberg, I; Wood, L, 2014) |
"Valproic acid is a widely used anticonvulsant drug with a broad therapeutic spectrum." | 6.73 | Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. ( Babaoglu, MO; Bilir, E; Bozkurt, A; Gunes, A; Yasar, U; Zengil, H, 2007) |
" We propose losartan, a drug approved by the US Food and Drug Administration, as an efficient antiepileptogenic therapy for epilepsy associated with vascular injury." | 3.80 | Losartan prevents acquired epilepsy via TGF-β signaling suppression. ( Bar-Klein, G; Cacheaux, LP; Cheng, P; Friedman, A; Heinemann, U; Kamintsky, L; Kaufer, D; Kim, SY; Prager, O; Schoknecht, K; Weissberg, I; Wood, L, 2014) |
"Valproic acid is a widely used anticonvulsant drug with a broad therapeutic spectrum." | 2.73 | Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. ( Babaoglu, MO; Bilir, E; Bozkurt, A; Gunes, A; Yasar, U; Zengil, H, 2007) |
" Furthermore, most preclinical antiepileptogenic studies lack information needed for translation, such as dose-blood level relationship, brain target engagement, and dose-response, and many use treatment parameters that cannot be applied clinically, for example, treatment initiation before or at the time of injury and dosing higher than tolerated human equivalent dosing." | 2.66 | Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? ( Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M, 2020) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 6 (60.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
Authors | Studies |
---|---|
Slomski, A | 2 |
Klein, P | 1 |
Friedman, A | 2 |
Hameed, MQ | 1 |
Kaminski, RM | 1 |
Bar-Klein, G | 2 |
Klitgaard, H | 1 |
Koepp, M | 1 |
Jozwiak, S | 1 |
Prince, DA | 1 |
Rotenberg, A | 1 |
Twyman, R | 1 |
Vezzani, A | 1 |
Wong, M | 1 |
Löscher, W | 1 |
Atanasova, D | 1 |
Tchekalarova, J | 1 |
Ivanova, N | 1 |
Nenchovska, Z | 1 |
Pavlova, E | 1 |
Atanassova, N | 1 |
Lazarov, N | 1 |
Nozaki, T | 1 |
Ura, H | 1 |
Takumi, I | 1 |
Kobayashi, S | 1 |
Maru, E | 1 |
Morita, A | 1 |
Palestro, PH | 1 |
Enrique, N | 1 |
Goicoechea, S | 1 |
Villalba, ML | 1 |
Sabatier, LL | 1 |
Martin, P | 1 |
Milesi, V | 1 |
Bruno Blanch, LE | 1 |
Gavernet, L | 1 |
Hong, S | 1 |
JianCheng, H | 1 |
JiaWen, W | 1 |
ShuQin, Z | 1 |
GuiLian, Z | 1 |
HaiQin, W | 1 |
Ru, Z | 1 |
Zhen, G | 1 |
HongWei, R | 1 |
Cacheaux, LP | 1 |
Kamintsky, L | 1 |
Prager, O | 1 |
Weissberg, I | 1 |
Schoknecht, K | 1 |
Cheng, P | 1 |
Kim, SY | 1 |
Wood, L | 1 |
Heinemann, U | 1 |
Kaufer, D | 1 |
Pereira, MG | 1 |
Becari, C | 1 |
Oliveira, JA | 1 |
Salgado, MC | 1 |
Garcia-Cairasco, N | 1 |
Costa-Neto, CM | 1 |
Ueno, Y | 1 |
Takagi, A | 1 |
Kawana, M | 1 |
Kasanuki, H | 1 |
Gunes, A | 1 |
Bilir, E | 1 |
Zengil, H | 1 |
Babaoglu, MO | 1 |
Bozkurt, A | 1 |
Yasar, U | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for losartan and Aura
Article | Year |
---|---|
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Topics: Acetylcysteine; Animals; Anticonvulsants; Antioxidants; Atorvastatin; Brain Injuries, Traumatic; Cef | 2020 |
1 trial available for losartan and Aura
Article | Year |
---|---|
Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients.
Topics: Adolescent; Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liq | 2007 |
8 other studies available for losartan and Aura
Article | Year |
---|---|
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan suppresses the kainate-induced changes of angiotensin AT
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Blood Pressure; Como | 2018 |
The angiotensin II type I receptor antagonist losartan retards amygdala kindling-induced epileptogenesis.
Topics: Amygdala; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Brain Injuries; Cerebral | 2018 |
Searching for New Leads To Treat Epilepsy: Target-Based Virtual Screening for the Discovery of Anticonvulsant Agents.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Ciprofloxacin; Da | 2018 |
Losartan inhibits development of spontaneous recurrent seizures by preventing astrocyte activation and attenuating blood-brain barrier permeability following pilocarpine-induced status epilepticus.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Brain; Disease Models, Animal; Epilepsy; Losartan; Male; N | 2019 |
Losartan prevents acquired epilepsy via TGF-β signaling suppression.
Topics: Animals; Animals, Newborn; Anticonvulsants; Astrocytes; Benzamides; Blood-Brain Barrier; Cells, Cult | 2014 |
Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticonv | 2010 |
Pulmonary hypertension during epileptic seizure with evidence of increased angiotensin II in pulmonary artery.
Topics: Aged; Angiotensin II; Anticonvulsants; Catheterization, Swan-Ganz; Drug Therapy, Combination; Epilep | 2005 |